Tims China Launches "Light Bagel Sandwich Lunch Box Series"
SHANGHAI, Feb. 18, 2025 (GLOBE NEWSWIRE) -- TH International Limited (NASDAQ: THCH), the exclusive operator of Tim Hortons coffee shops in China ('Tims China' or the 'Company') today announced the launch of its "Light Bagel Sandwich Lunch Box Series", enhancing its commitment to providing high-quality, convenient coffee and warm, healthy food experiences. Centered around a bagel sandwich + salad + coffee combination, this new lunch offering targets urban consumers seeking convenient and healthy meal options, tapping into a new trend in healthy Western-style lunches.[Tims China "Light Bagel Sandwich Lunch Box Series"]
"Light Bagel Sandwich Lunch Box" Launches Nationwide, Focusing on the Lunch Dining Experience
Starting February 18, the Light Bagel Sandwich Lunch Box will be available at Tims China stores nationwide. The three-piece set includes: a freshly toasted, warm bagel sandwich, a fresh vegetable salad*, and a healthy beverage. The series offers eight bagel sandwich varieties, five side dishes, and eleven beverage options, allowing customers to customize combinations according to their personal tastes and nutritional preferences.
With Tims' "Chibaobao Card" 40% discount, prices start from just RMB 25.8, offering both high nutritional value and cost-effectiveness. Whether it's for office workers during lunch breaks, post-workout nutrition, or sharing with friends and family, the Lunch Box brings a delightful and convenient experience to every customer.
Furthermore, the Lunch Box series caters to today's consumers' preference for "light and low-calorie" options. Every ingredient has passed strict quality and calorie control, meeting modern consumers' dual demands for flavorful and healthy. All beverages adhere to our "5-Zero" commitment – no non-dairy creamer, no artificial creamer, no hydrogenated vegetable oils, no trans fats, and no instant tea powder – offering consumers more transparency and reliability with their choices.
Reimagining Healthy Lunches: Bagel + Salad + Coffee
Moving away from traditional fast food combinations of sandwiches, fries, and sodas, Tims China's sandwiches feature high-fiber bagels paired with premium proteins including chicken breast, tuna, and beef. Options include the Avocado Chicken Bagel Sandwich, Black Truffle Bacon Angus Bagel Sandwich, and the newly introduced Teriyaki Chicken Thigh Bagel Sandwich. The salads include seasonal fresh vegetables, while the beverage selection includes Americano coffee and low-calorie lemon water, providing a nutritionally balanced and satisfying yet light lunch option.
The Lunch Box's portable packaging is designed for both dine-in and takeaway convenience, addressing the flexibility that urban professionals need.
Yongchen Lu, CEO of Tims China, commented: "We are delighted to introduce the Light Bagel Sandwich Lunch Box Series, offering our customers new convenient and delicious lunch options. This series marks a meaningful expansion of Tims China's lunch menu. It delivers a fresh dining experience to consumers, meeting a wide range of needs from fitness-focused meals to light office lunches. I am excited about the market potential of our new series."
Note:
*Salads are currently available in seven cities: Beijing, Shanghai, Guangzhou, Shenzhen, Qingdao, Yangzhou, and Hangzhou. Customers in other regions can enjoy a selection of snack alternatives.
ABOUT TH INTERNATIONAL LIMITED
TH International Limited (Nasdaq: THCH) ('Tims China') is the parent company of the exclusive master franchisee of Tim Hortons coffee shops in mainland China, Hong Kong, and Macau. Tims China was founded by Cartesian Capital Group and Tim Hortons Restaurants International, a subsidiary of Restaurant Brands International (TSX: QSR) (NYSE: QSR).
The company's philosophy is rooted in world-class execution and data-driven decision making and centered around true local relevance, continuous innovation, genuine community, and absolute convenience. For more information, please visit https://www.timschina.com.
Contacts
Investor RelationsIR@timschina.com or Gemma.Bakx@cartesiangroup.com
Public Relationspatty.yu@timschina.com
Follow @TimHortonsChina
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/4555dcdc-7d52-4946-8c08-4b0902a9d8dcSign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
13 minutes ago
- Yahoo
Ethereum Treasury Firm SharpLink Gaming Plunges 70% – But There May Be a Twist
SharpLink Gaming (SBET), a Nasdaq-listed company that is pursuing an ether ETH treasury strategy, tumbled 70% on Thursday in after-hours trading following a fresh filing to the U.S. Securities and Exchange Commission. The company submitted an S-3ASR registration statement, enabling the resale of up to 58,699,760 shares related to its private investment in public equity (PIPE) financing. The Thursday filing allows more than 100 shareholders in the PIPE round to sell their shares, effectively flooding the market and triggering a post-close sell-off, Charles Allen, CEO of BTCS, a publicly-traded firm that's pursuing crypto reserve strategy, explained in an X post and an interview with CoinDesk. The company raised $450 million earlier this month through a PIPE round from a wide range of investors, including ConsenSys, Galaxy, and Pantera Capital, to acquire ETH for its treasury. Ethereum co-founder and ConsenSys CEO Joseph Lubin also joined the firm as board chairman. However, there may be a larger strategy behind the latest move. Allen said in an X post that he thinks the company may have quietly raised up to $1 billion to buy more ETH using an at-the-market (ATM) offering that was previously announced in a May 30 SEC filing. "If they played cards right, they would expect a surprise PR tomorrow with $1B of ETH purchases, which could light the match to reignite the stock," he said. ETH is down 4.1% over the past 24 hours at around $2,650 as bitcoin and the broader crypto markets slid.
Business Upturn
an hour ago
- Business Upturn
Transgene to Participate in Upcoming Meetings with Biotech Industry Leaders
By GlobeNewswire Published on June 13, 2025, 11:30 IST Strasbourg (France), June 13, 2025, 8:30 a.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announced that its management team will meet institutional investors, scientists and leaders of the biotechnology ecosystem during the upcoming editions of: BIO International Convention 2025 , on June 16, in Boston, US; , on June 16, in Boston, US; Portzamparc – 2025 Mid&Small Caps Conference (hosted by BNP Paribas Group ), on June 18, in Paris, France; (hosted by ), on June 18, in Paris, France; International Neoantigen Summit , on June 24, 2025, in Amsterdam, Netherlands; , on June 24, 2025, in Amsterdam, Netherlands; International Academy of Oral Oncology 2025 (IAOO), on July 18, in Liverpool, UK. Following the positive clinical data on our individualized neoantigen cancer vaccine TG4050, presented at the American Society of Clinical Oncology (ASCO) Annual Meeting (see press release here), Transgene together with Prof. Christian Ottensmeier, MD, PhD, FRCP (University of Liverpool, La Jolla Institute for Immunology), have discussed the data presented, the unmet medical need and current treatment landscape for patients suffering from head and neck cancers in a virtual event available on Transgene website and here. *** About Transgene Transgene (Euronext: TNG) is a biotechnology company focused on designing and developing targeted immunotherapies for the treatment of cancer. The Company's clinical-stage programs consist of a portfolio of viral vector-based immunotherapeutics. TG4050, the first individualized therapeutic vaccine based on the myvac® platform is the Company's lead asset, with demonstrated proof of principle in patients in the adjuvant treatment of head and neck cancers. The portfolio also includes other viral-vector-based immunotherapies: TG4001 for the treatment of HPV-positive cancers, as well as BT-001 and TG6050, two oncolytic viruses based on the viral backbone. The Company also conducts innovative discovery and preclinical work, aimed at developing novel viral vector-based modalities. With Transgene's myvac® platform, therapeutic vaccination enters the field of precision medicine with a novel immunotherapy that is fully tailored to each individual. The myvac® approach allows the generation of a virus-based immunotherapy that encodes patient-specific mutations identified and selected by Artificial Intelligence capabilities provided by its partner NEC. With its proprietary platform Transgene is building on its viral vector engineering expertise to design a new generation of multifunctional oncolytic viruses. Additional information about Transgene is available at: Follow us on social media: X (formerly Twitter): @TransgeneSA — LinkedIn: @Transgene — Bluesky: @Transgene Contacts Disclaimer This press release contains forward-looking statements, which are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. The occurrence of any of these risks could have a significant negative outcome for the Company's activities, perspectives, financial situation, results, regulatory authorities' agreement with development phases, and development. The Company's ability to commercialize its products depends on but is not limited to the following factors: positive pre-clinical data may not be predictive of human clinical results, the success of clinical studies, the ability to obtain financing and/or partnerships for product manufacturing, development and commercialization, and marketing approval by government regulatory authorities. For a discussion of risks and uncertainties which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ('Facteurs de Risque') section of the Universal Registration Document, available on the AMF website ( or on Transgene's website ( Forward-looking statements speak only as of the date on which they are made, and Transgene undertakes no obligation to update these forward-looking statements, even if new information becomes available in the future. Attachment 20250613_Transgene_Upcoming_Events_EN Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Yahoo
an hour ago
- Yahoo
Hooker Furnishings Corp (HOFT) Q1 2026 Earnings Call Highlights: Navigating Challenges with ...
Consolidated Net Sales: $85.3 million, a decrease of $8.3 million or 8.8% compared to the same period last year. Operating Loss: Reduced by $1.6 million or 31% to $3.6 million. Operating Expenses: Reduced by $2.2 million despite $523,000 in restructuring costs. Gross Margin Improvement: Increased by 190 basis points. Net Loss: $3.1 million or $0.29 per diluted share, improved from the prior year's net loss of $4.1 million or $0.39 per diluted share. Hooker Branded Segment: Achieved breakeven for the quarter. Domestic Upholstery Segment: Operating losses reduced by 55%. Home Meridian Segment: Operating losses reduced by 17%. Cash and Cash Equivalents: $18 million, an increase of $11.7 million from year-end. Inventory Levels: Decreased from about $71 million at year-end to about $64 million at quarter end. Available Borrowing Capacity: About $40 million under revolving credit facility as of quarter end. Cost Reduction Strategy: Aimed at achieving approximately $25 million in annualized savings by next fiscal year. Vietnam Warehouse: Opened a new facility to enhance supply chain efficiency and reduce lead times from about six months to four to six weeks. Warning! GuruFocus has detected 3 Warning Signs with HOFT. Release Date: June 12, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Hooker Furnishings Corp (NASDAQ:HOFT) reduced its operating loss by $1.6 million or 31% compared to the previous year, reflecting successful cost reduction initiatives. The company improved gross margins by 190 basis points, driven by better margins at Home Meridian and Domestic Upholstery. Hooker Branded achieved breakeven for the quarter, and Domestic Upholstery and Home Meridian significantly reduced their operating losses by 55% and 17%, respectively. The new Vietnam warehouse is expected to enhance supply chain efficiency, reducing lead times from about six months to four to six weeks, with positive initial customer feedback. The company anticipates achieving approximately $25 million in annualized savings by the next fiscal year through its multipronged cost reduction strategy. Consolidated net sales decreased by $8.3 million or 8.8% compared to the same period last year, primarily due to a double-digit sales decrease at Home Meridian. The home furnishings industry is facing challenges due to persistent softness in the housing market, higher mortgage rates, and declining consumer sentiment. Import tariffs have sharply curtailed demand in the mid-price segment, impacting Home Meridian's sales. The company recorded a net loss of $3.1 million or $0.29 per diluted share, although this was an improvement from the prior year's first quarter. Uncertainties around import tariffs, particularly for products sourced from Vietnam, continue to create significant uncertainty and impact consumer confidence. Q: Can you comment on the cadence of shipments from February through April, particularly after Liberation Day? A: The cadence changed drastically due to tariffs, affecting the HMI customer more than the Hooker Branded and Domestic Upholstery side of our business. - Jeremy Hoff, CEO Q: What drove the higher orders at Hooker Legacy brands in May, and any updates on HMI since April? A: The increase is due to our broadened merchandising strategy with collected living, which is starting to show positive effects. For HMI, there's still significant uncertainty due to tariffs, particularly with the upcoming July 9 date. - Jeremy Hoff, CEO Q: How will the cost savings initiatives progress for the rest of the year? A: We expect about $2.5 million less in costs compared to last year due to Phase 1. Phase 2 initiatives will have a $250,000 positive impact in Q2, with significant savings expected in Q4, around $3.5 million. - Earl Armstrong, CFO Q: What are your capital allocation priorities after dividends and debt? Could there be share buybacks? A: Strengthening the balance sheet is our top priority, followed by dividends. We have no current plans for share buybacks. - Jeremy Hoff, CEO Q: Do you expect the strong May performance to continue throughout the year, and how will seasonality affect revenue? A: Historically, the second half is stronger than the first. While May was strong, it's uncertain if this momentum will continue throughout the year. - Jeremy Hoff, CEO For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus.
